Nomura Establishes Japanese Generics And Biotech Investment Funds
This article was originally published in PharmAsia News
Japanese investment bank Nomura announced June 18 that it would establish investment funds containing a basket of generic drug makers and biotech companies June 24. Nomura Asset Management hopes to capitalize on current and future growth in the sectors. Japanese generic makers' share prices jumped on the news. Towa Pharmaceutical led the pack with ¥220 up for the day, marking a new high for the year. Saiwai Pharmaceutical's share price also increased by ¥170 to ¥5,270, also a new high for Japan's largest generic maker. Nichi-Iko shares rose for four days in a row. Another maker Fuji Pharmaceutical, however, saw shares drop by ¥18 due to heavy dependence on a single distributor. Since a diagnostic procedure combined payment system is expanding among hospitals in Japan, the generic drug market is expected to grow further. (Click here for more - Japanese language
You may also be interested in...
Indoco has tripled its operating profit in its financial first quarter ended 30 June 2020. The company has also received FDA approval for its generic version of Eli Lilly’s Zyprexa.
With the Janssen and Novavax deals, the UK has now secured access to six different candidates across four different vaccine types.
Council of Europe Directorate EDQM finds popular paracetamol products sold in the Netherlands and manufactured in China do not contain unsafe levels of a possible human carcinogen as reported in the Dutch media.